Cagrilintide
Long-acting amylin analog for weight management
Overview
Cagrilintide is a long-acting analog of human amylin, a hormone co-secreted with insulin that regulates appetite and glucose metabolism. It works synergistically with GLP-1 agonists for enhanced weight loss.
Mechanism of Action
Activates amylin receptors in the brain → reduces appetite and food intake → slows gastric emptying → improves glycemic control → synergizes with GLP-1 pathway.
Benefits
- Significant appetite suppression
- Enhanced weight loss with GLP-1 combo
- Improved glycemic control
- Once-weekly dosing
- Complementary mechanism to GLP-1
Dosing Protocol
Half-Life
~7 days
Duration of pharmacological activity after administration.
Side Effects
- Nausea
- Diarrhea
- Injection site reactions
- Decreased appetite
Stacking Recommendations
Storage & Reconstitution
Refrigerate at 2–8°C. Do not freeze. Protect from light.
Research Notes
In Phase 3 trials as CagriSema (cagrilintide + semaglutide), showing up to 25% body weight loss. Novo Nordisk development. Potential to surpass individual GLP-1 agents.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.